08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On February 11, 2020, the Equal Employment Opportunity Commission (EEOC) filed a complaint in Connec...
Read More >
Cornrows or locs may not fit your corporate image, but be careful: state and local legislation prohi...
Read More >
Before employers implement their proposed workforce changes resulting from the finalization of the n...
Read More >
Risk in construction contracts - 'Risk', in a project delivery context, can be defined as 'an uncer...
Read More >
EE Ltd v. Sir James H E Chichester [2019] UKUT 164 (LC) considers the ability of landowners to resis...
Read More >
On January 9, 2020, the National Institute of Statistics and Geography (INEGI by its acronym in Span...
Read More >